Results 21 to 30 of about 179,002 (365)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study [PDF]

, 2020
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids.
Grupo Español de Trasplante Hematopoyético (GETH), Parody, Rocío, Sánchez Ortega, Isabel   +2 more
core   +4 more sources

Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial

Frontiers in Immunology, 2020
Chronic graft-versus-host-disease (cGVHD) is the leading cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation(HSCT). There is no standard therapy for patients refractory or dependent to corticosteroid treatment. We
Liren Qian, Miao Liu, Jianliang Shen, Jian Cen, Defeng Zhao   +4 more
doaj   +1 more source

Ocular graft-versus-host disease: An update on immune pathogenesis and therapies

Medicina Universitaria, 2022
Hematopoietic stem cell transplantation (HSCT) is a treatment option for hematological and non-hematological diseases that do not respond to conventional treatments.
Samantha P. Peña-Lozano, Luz M. Barbosa-Castillo, Adriana E. Partida-García, Perla R. Colunga-Pedraza   +3 more
doaj   +1 more source

Is it possible to separate the graft-versus-leukemia (GVL) effect against B cell acute lymphoblastic leukemia from graft-versus-host disease (GVHD) after hematopoietic cell transplant? [PDF]

, 2022
Hematopoietic cell transplant is a curative therapy for many pediatric patients with high risk acute lymphoblastic leukemia. Its therapeutic mechanism is primarily based on the generation of an alloreactive graft-versus-leukemia effect that can eliminate
Bhatt, Sima T, Buxbaum, Nataliya Prokopenko, Cuvelier, Geoffrey D E, Kitko, Carrie L, Li, Amanda M, Rozmus, Jacob, Schultz, Kirk R   +6 more
core   +2 more sources

Patient-reported outcomes and health status associated with chronic graft-versus-host disease

Haematologica, 2018
Chronic graft-versus-host disease occurs in 20–50% of allogeneic hematopoietic cell transplant survivors. We surveyed patients about their quality of life, symptoms, health status, comorbid conditions and medications.
Stephanie J. Lee, Lynn Onstad, Eric J. Chow, Bronwen E. Shaw, Heather S.L. Jim, Karen L. Syrjala, K. Scott Baker, Sarah Buckley, Mary E. Flowers   +8 more
doaj   +1 more source

Graft versus host disease after liver transplantation following radiotherapy for the treatment of hepatocellular carcinoma: A case report and literature review

SAGE Open Medical Case Reports, 2022
Graft versus host disease after solid organ transplantation is very rare. This article reports a case of graft versus host disease after liver transplantation following targeted therapy and radiotherapy for the treatment of hepatocellular carcinoma.
Zijun Chen, Chuangye Han, Xiangkun Wang, Yongfei He, Tianyi Liang, Shutian Mo, Xuan Li, Guangzhi Zhu, Hao Su, Xinping Ye, Zili Lv, Liming Shang, Zhang Wen, Minhao Peng, Tao Peng   +14 more
doaj   +1 more source

Vitiligo: an uncommon cutaneous manifestation of graft versus host disease

Pigment International, 2022
Graft versus host disease (GVHD) is the most serious complication of hematopoietic stem cell transplantation. Skin is the most commonly affected organ, in both acute and chronic GVHD with a variable clinical spectrum of presentation with the typical skin
Preema Sinha, Anwita Sinha, Subramaniyan Radhakrishnan, Jasvinder Kaur Bhatia   +3 more
doaj   +1 more source

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

Haematologica, 2018
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease.
Sarah Nikiforow, Tao Wang, Michael Hemmer, Stephen Spellman, Görgün Akpek, Joseph H. Antin, Sung Won Choi, Yoshihiro Inamoto, Hanna J. Khoury, Margaret MacMillan, David I. Marks, Ken Meehan, Hideki Nakasone, Taiga Nishihori, Richard Olsson, Sophie Paczesny, Donna Przepiorka, Vijay Reddy, Ran Reshef, Hélène Schoemans, Ned Waller, Daniel Weisdorf, Baldeep Wirk, Mary Horowitz, Amin Alousi, Daniel Couriel, Joseph Pidala, Mukta Arora, Corey Cutler   +28 more
doaj   +1 more source

B-cell involvement in chronic graft-versus-host disease

Haematologica, 2008
Chronic graft-versus-host disease is a serious complication in long-term survivors of allogeneic hematopoietic stem cell transplantation, with several organ systems affected.
Rick Kapur, Saskia Ebeling, Anton Hagenbeek   +2 more
doaj   +1 more source

Pathogenesis of graft-versus-host-disease [PDF]

Biology of Blood and Marrow Transplantation, 2005
Sale, George E.
openaire   +4 more sources